BACKGROUND: The aim of this retrospective study was to compare the prognosis of patients with esophageal cancer after non-curative endoscopic resection (ER) followed by esophagectomy (ER + S) with that of patients after primary surgery (PS). METHODS: Between 2000 and 2015, 287 patients had esophagectomy for T1 esophageal cancer. 81 of these patients underwent at least one ER in curative intention before surgery (7 squamous cell carcinomas, 74 adenocarcinomas). Indications for esophagectomy were R1-resection, submucosal infiltration, multifocality, long-segment Barrett esophagus, recurrence, postinterventional stenosis or a combination of these factors. Using propensity-score matching with gender, age, year of diagnosis, tumor localization, mucosal/submucosal infiltration and histology, the clinicopathologic and survival data of these patients were compared to those of 81 patients after PS (median follow-up: 5.5 years). RESULTS: There were no significant differences between both groups concerning number of resected lymph nodes and percentage of nodal metastasis (9.3% total). 9% of esophagectomy specimens after ER showed pT2/pT3-tumors. The 5-year survival rate was 86% in the PS and 85% in the ER + S group (p = 0.498). The disease-free survival was 85% in patients with ER + S and 98% in PS (p < 0.005). The recurrence rate after esophagectomy was higher after ER + S compared to PS (p = 0.015). More than 3 months time delay between ER and surgery was associated with reduced survival, but only within the first postinterventional year. CONCLUSIONS: As the disease-free survival was inferior in the ER + S compared to the PS group the indication for ER, especially repeated ERs, should be restricted to cases with high expectation of success.
BACKGROUND: The aim of this retrospective study was to compare the prognosis of patients with esophageal cancer after non-curative endoscopic resection (ER) followed by esophagectomy (ER + S) with that of patients after primary surgery (PS). METHODS: Between 2000 and 2015, 287 patients had esophagectomy for T1 esophageal cancer. 81 of these patients underwent at least one ER in curative intention before surgery (7 squamous cell carcinomas, 74 adenocarcinomas). Indications for esophagectomy were R1-resection, submucosal infiltration, multifocality, long-segment Barrett esophagus, recurrence, postinterventional stenosis or a combination of these factors. Using propensity-score matching with gender, age, year of diagnosis, tumor localization, mucosal/submucosal infiltration and histology, the clinicopathologic and survival data of these patients were compared to those of 81 patients after PS (median follow-up: 5.5 years). RESULTS: There were no significant differences between both groups concerning number of resected lymph nodes and percentage of nodal metastasis (9.3% total). 9% of esophagectomy specimens after ER showed pT2/pT3-tumors. The 5-year survival rate was 86% in the PS and 85% in the ER + S group (p = 0.498). The disease-free survival was 85% in patients with ER + S and 98% in PS (p < 0.005). The recurrence rate after esophagectomy was higher after ER + S compared to PS (p = 0.015). More than 3 months time delay between ER and surgery was associated with reduced survival, but only within the first postinterventional year. CONCLUSIONS: As the disease-free survival was inferior in the ER + S compared to the PS group the indication for ER, especially repeated ERs, should be restricted to cases with high expectation of success.
Entities:
Keywords:
Early esophageal cancer; Endoscopic resection; Esophagectomy; Prognosis; Recurrence; T1 esophageal cancer
Authors: Oliver Pech; Elfriede Bollschweiler; Hendrik Manner; Jessica Leers; Christian Ell; Arnulf H Hölscher Journal: Ann Surg Date: 2011-07 Impact factor: 12.969
Authors: Daniela Molena; Francisco Schlottmann; Joshua A Boys; Shanda H Blackmon; Karen J Dickinson; Christy M Dunst; Wayne L Hofstetter; Michal J Lada; Brian E Louie; Benedetto Mungo; Thomas J Watson; Steven R DeMeester Journal: J Gastrointest Surg Date: 2016-08-25 Impact factor: 3.452
Authors: Joshua A Boys; Stephanie G Worrell; Parakrama Chandrasoma; John G Vallone; Dipen M Maru; Lizhi Zhang; Shanda H Blackmon; Karen J Dickinson; Christy M Dunst; Wayne L Hofstetter; Michael J Lada; Brian E Louie; Daniela Molena; Thomas J Watson; Steven R DeMeester Journal: J Gastrointest Surg Date: 2015-09-25 Impact factor: 3.452
Authors: Arjun Pennathur; Andrew Farkas; Alyssa M Krasinskas; Peter F Ferson; William E Gooding; Michael K Gibson; Matthew J Schuchert; Rodney J Landreneau; James D Luketich Journal: Ann Thorac Surg Date: 2009-04 Impact factor: 4.330
Authors: Valerie A Williams; Thomas J Watson; Fernando A Herbella; Oliver Gellersen; Daniel Raymond; Carolyn Jones; Jeffrey H Peters Journal: J Gastrointest Surg Date: 2007-10-02 Impact factor: 3.452
Authors: Ganapathy A Prasad; Tsung Teh Wu; Dennis A Wigle; Navtej S Buttar; Louis-Michel Wongkeesong; Kelly T Dunagan; Lori S Lutzke; Lynn S Borkenhagen; Kenneth K Wang Journal: Gastroenterology Date: 2009-06-12 Impact factor: 22.682
Authors: Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Chi-Fu J Yang; Hanghang Wang; David H Harpole; Thomas A D'Amico Journal: J Thorac Cardiovasc Surg Date: 2019-10-08 Impact factor: 5.209
Authors: Max Krämer; Patrick S Plum; Oscar Velazquez Camacho; Kat Folz-Donahue; Martin Thelen; Isabel Garcia-Marquez; Christina Wölwer; Sören Büsker; Jana Wittig; Marek Franitza; Janine Altmüller; Heike Löser; Hans Schlößer; Reinhard Büttner; Wolfgang Schröder; Christiane J Bruns; Hakan Alakus; Alexander Quaas; Seung-Hun Chon; Axel M Hillmer Journal: Mol Oncol Date: 2020-04-21 Impact factor: 6.603
Authors: Patrick Sven Plum; Heike Löser; Thomas Zander; Ahlem Essakly; Christiane J Bruns; Axel M Hillmer; Hakan Alakus; Wolfgang Schröder; Reinhard Büttner; Florian Gebauer; Alexander Quaas Journal: J Cancer Res Clin Oncol Date: 2020-12-10 Impact factor: 4.553